Targeted DRUG-seq service

Benefits

Custom-developed panels: Users communicate their targets of interest, and we will develop ad-hoc detection panels.

Up to 100 targets: Experimentally validated panels for differential expression analysis.

No prior RNA extraction needed: Optimized lysis buffers for complete lysis.

Minimal sequencing cost: By only sequencing the targets, sequencing costs are drastically decreased.

MERCURIUS^TM

The MERCURIUS™ Targeted DRUG-seq service offers the most comprehensive, high-throughput and cost-efficient solution for targeted gene expression analysis projects starting from 2D cell cultures.

As part of the Targeted DRUG-seq service, clients share their genes of interest with us, we develop a corresponding custom detection panel and validate it directly on their RNA samples.

As part of the Targeted DRUG-seq service, we send our clients a proprietary Cell Lysis Buffer which is optimized for both cell lysis and downstream enzymatic reactions, without having to perform RNA extraction in between.

After mixing the Lysis Buffer with their cells, the client can return their cell lysates to us to be used for panel validation.

Once the targeted gene panel validation is complete, we will inform the client that the dedicated service is correctly established and that we are ready to receive their test samples.

By combining the advantages of the targeted approach with the DRUG-seq system, up to 100 different genes can be assessed across tens to thousands of samples in parallel, significantly reducing the time and costs associated with library preparation and sequencing.

As a result of our service, our clients receive raw sequencing data (fastq files), gene count matrices and analysis reports files.

Optional downstream differential gene expression analysis are also available upon request.